Characterisation of the ovine model of McArdle's disease: development of therapeutic strategies by Walker, Kendall Rae
 
Characterisation of the Ovine Model 
of McArdle’s Disease: Development 
of Therapeutic Strategies. 
 
Kendall Rae Walker BSc (Hons.)  
 











“This thesis is presented for the degree of Doctor of 














I declare that this thesis is my own account of my research and contains as its 
main content work that has not previously been submitted for a degree at any 






Kendall Rae Walker 
   ii  iii
Abstract 
 
Characterisation of the Ovine Model of McArdle’s Disease: Development of 
Therapeutic Strategies. 
McArdle’s disease (OMIM 232600) is one of the most common glycogen storage 
diseases affecting skeletal muscle. It is inherited in an autosomal recessive manner 
and is caused by a defect in the muscle glycogen phosphorylase gene (PYGM) (Ch 
11q13), a key metabolic enzyme. As a result, patients are unable to mobilise muscle 
glucose stores to provide the energy for muscle contraction; and suffer from exercise 
intolerance (myalgia, tachycardia, breathlessness and early fatigue) as well as cramps 
/ contractures and occasionally rhabdomyolysis and myoglobinuria after bouts of 
strenuous exercise. Histopathologically, McArdle’s disease is characterised by an 
increase in subsarcolemmal storage of glycogen and reduced or absent glycogen 
phosphorylase activity. McArdle’s disease displays significant genetic heterogeneity, 
with 47 different disease-causing mutations in PYGM having been identified in human 
sufferers. In keeping with this genetic heterogeneity, significant molecular 
heterogeneity is observed in patients with regard to the effect of the disease-causing 
mutation on the PYGM mRNA transcript. In contrast, little biochemical heterogeneity is 
associated with the disease, with approximately 90% of human patients having no 
residual pygm protein and therefore no enzyme activity. 
 
A naturally occurring ovine model of McArdle’s disease was identified a number of 
years ago in a flock of merino sheep in Western Australia. The disease causing 
mutation responsible for ovine McArdle’s disease was identified and published in 1997 
by Tan et al., (1997) [1]. The mutation occurs in the 3’ acceptor splice-site of intron 19 
of the ovine PYGM gene, resulting in the activation of a cryptic splice-site site in exon 
20 and the premature termination of the transcript. Hypothetically this mutant pygm 
protein should be 31 amino acids smaller than the wild-type. When I began my PhD, it 
was known that the ovine sufferers displayed exercise intolerance and histological   iv
examination of affected muscle revealed an excess subsarcolemmal storage of 
glycogen and absent phosphorylase, as occurs in their human counterparts. Due to 
their similarities in muscle mass to humans and the relative ease and low cost of 
maintenance, the ovine model of McArdle’s disease is an important and highly relevant 
test-bed for therapeutic strategies.  
 
This thesis can essentially be divided into two parts: 
1) The characterisation of the ovine model of McArdle’s disease- 
In particular, determining the effect of the disease-causing mutation on both the PYGM 
mRNA and protein, characterising the sequences of the ovine glycogen phosphorylase 
isoforms and their developmental and tissue specific expression patterns, as well as 
determining the identity and the activity of the glycogen phosphorylase isoforms 
expressed in certain muscle groups (cardiac, extraocular and smooth muscles) which 
appear to be protected from the disease.  
 
Based upon this data and making use of the ovine model; 
2) Development of therapeutic strategies- 
A number of potential therapeutic strategies were investigated including:  
•  The upregulation of a functionally related gene, through the re-expression of 
non-muscle isoforms of glycogen phosphorylase via notexin induced muscle 
regeneration.  
•  As well as the replacement of the PYGM gene using modified adenovirus 5 
(AdV5) and adeno-associated virus 2 (AAV-2) vectors.  
 
Based upon the ability of the non-muscle isoforms of glycogen phosphorylase to 
function in-vivo in McArdle’s muscle in the absence of the muscle isoform, the ability of 
tributyrin (a butyrate prodrug and potent histone deacetylase inhibitor) to re-express 
brain glycogen phosphorylase in mature mouse muscle was also investigated.   v
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Table 2.3.9:PCR primers used to characterise the ovine PYGB 3’UTR transcripts. 
PCR primers used to characterise ovine PYGB 3' UTR transcripts 
Fragment  Primer Combination  Expected Size (bp) 
1  A: 5' ctcgggaccagctttcatc 3' 
B: 5' ggtcacgcttggcctaaag 3' 
1067 
2  A: 5' ctcgggaccagctttcatc 3' 
C: 5' tgctattttccgttgctaaaa 3' 
656 
3  A: 5' ctcgggaccagctttcatc 3' 
E: 5' cacaccttgctgggttttt 3' 
826 
4  D: 5' gagcgtcagctgggtgtt 3' 




D: 5' gagcgtcagctgggtgtt 3' 





































Figure 2.3.5 PCR amplification strategy and probes for northern blot analysis to confirm 
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Table 2.3.10: PCR primers used to characterise the ovine PYGL 3’UTR. 
PCR primers used to characterise ovine PYGL 3' UTR transcripts 
Fragment  Primer Combination  Expected Size (bp) 
1  A: 5' aattctccagtgaccgaacg 3' 
E: 5' tttcccttccaatttccaga 3' 
232 
2  A: 5' aattctccagtgaccgaacg 3' 
B: 5' cttcatggcagagcagacag 3' 
436 
3  C: 5' gagggcactacttcctggtg 3' 
B: 5' cttcatggcagagcagacag 3' 
309 
4  D: 5' gcttcttactggacttgaacattt 3' 




C: 5' gagggcactacttcctggtg 3' 





































Figure: 2.3.6 PCR amplification strategy and probes for northern blot analysis to confirm 
3'UTR splicing of ovine PYGL. 
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Fig. 2.4.1: PYGB 3’RACE products 
analysed on a 1.5% agarose gel.
Key:
Lane 1: 100bp ladder
Lane 2: 3’RACE sample 1

















Figure 2.4.2: Sequence of ovine PYGB 3’UTR transcript A and transcript B. 
Note: Stop codon of exon 20 indicated in red, polyadenylation signals underlined
773000bp
1000bp
Fig. 2.4.3: PCR analysis of ovine 
PYGB 3’UTR transcripts on a 1% 
agarose gel.
Key:
Lane 1: 100bp ladder
Lane 2: Fragment 1 expected size: 1067bp
Lane 3: Fragment 2 expected size: 656bp
Lane 4: Fragment 3 expected size: 826bp
Lane 5: Fragment 4 expected size: 163bp
Lane 6:Fragment 5 (-ve control)
Lane 7: 100bp ladder
1   2  3  4   5  6  7
Fragment 1
Fragment 3
Fragment 2 Fragment 4
Fragment 2



















Sequence in common between UTR A and UTR B.
Sequence specific to UTR A
Sequence specific to UTR B
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C) Fragment 3 amplified from ovine genomic DNA
791000bp
3000bp
Fig. 2.4.8: PYGL 3’RACE 
products analysed on a 
1.5% agarose gel.
Key:
Lane 1: 100bp ladder
Lane 2: 3’RACE sample 1





















Figure 2.4.9: Sequence of ovine PYGL 3’UTR transcript A and transcript B. 
Note: Stop codon of exon 20 indicated in red, polyadenylation signals 
underlined. Probe C used in northern blot highlighted in blue.
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Fig. 2.4.10: PCR analysis of ovine 
PYGL 3’UTR transcripts on a 1% 
agarose gel.
Key:
Lane 1: 100bp ladder
Lane 2: Fragment 1 expected size: 232bp
Lane 3: Fragment 2 expected size: 436bp
Lane 4: Fragment 3 expected size: 309bp
Lane 5: Fragment 4 expected size: 99bp
Lane 6:Fragment 5 (-ve control)
Lane 7: 100bp ladder
4.2kb
3.3kb
18s rRNA Internal 
standard
Figure 2.4.11: Northern blot 
analysis of 10μg of total RNA 
with ovine PYGL probe C.
Key:
Lane 1: Adult ewe liver RNA





Figure 2.4.12: Northern blot analysis of 10μg of total RNA 
with ovine PYGL probe C.
Key:
A)
Lane 1: Occipital lobe RNA
Lane 2: Temporal Lobe RNA
B)
Lane 3: Heart RNA
Lane 4: Semitendinosus RNA
854.2kb




Figure 2.4.5: Northern blot analysis 
of 10μg of total RNA with ovine 
PYGB probe A.
Key:
Lane 1: Adult ewe heart RNA
Lane 2: Fetal heart RNA.
Figure 2.4.6: MscI digestion of 
ovine genomic DNA analysed on 
a 3% agarose/TBE gel.
Key:
Lane 1: 100bp ladder
Lane 2: homozygous c.1249G
Lane 3: homozygous c.1249A
Lane 4: heterozygous c1249G/A
Figure 2.4.7: Schematic representation of the conservation of Ala416 in 
mammalian and non-mammalian glycogen phosphorylases.
NQRHLDHVAALFPGDVDRL Sheep pygb (alanine)
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Key: - not detected
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Table 2.4.6: Results of semi-quantitative RT-PCR analysis of ovine tissues.
Figure 2.4.14: Analysis of PCR products from semi-
quantitative RT-PCR of ovine tissues.
A: PYGB (29 cycles) B: PYGM (28 cycles) C: PYGL (30 cycles) 
D: 18s rRNA (24 cycles) E: HPRT (28 cycles)
89Figure 2.4.13: Phylogenetic analysis of mammalian and non-mammalian glycogen
phosphorylase protein sequences.
87Figure 3.4.1: SDS-PAGE of insect cell
lysates used for the double 
homologous recombination to 
generate recombinant baculoviruses 
Ala416PYGB and Thr416PYGB. 
4-20% Tris-glycine polyacrylamide 
gel stained with Coomassie Blue.
Key:
1: Unchallenged Sf9 insect cell lysate
2: Ala416PYGB insect cell lysate 
3: Unchallenged Sf9 insect cell lysate
4: Thr416PYGB insect cell lysate.
Figure 3.4.2: Western Blot 
using pygb specific polyclonal 
antibody (1:3,500 dilution).
Key: As for Figure 3.4.1.
AB
Figure 3.4.3: Native gel activity assay of insect cell lysates used for the double 
homologous recombination to generate recombinant baculoviruses Ala416PYGB 
and Thr416PYGB. IEF gel pH 3-10 (BioRad),A: no allosteric effectors B: incubated in 
5mM AMP, stained with KI/I2.
Key: 
1: Unchallenged Sf9 insect cell lysate
2: Ala416PYGB insect cell lysate 
3: Thr416PYGB insect cell lysate.
Note: ‘a’ denotes phosphorylated protein,  ‘b’ denotes non-phosphorylated protein.
100kDa
100kDa
115Figure 3.4.4: SDS-PAGE of 10μg of insect cell lysates from the time-course 
experiments. 4-20% Tris-glycine polyacrylamide gel stained with 
coomassie blue.
A: Ala416pygb cell lysates. B: Thr416pygb cell lysates.
Key:
1: Unchallenged Sf9 insect cell lysate
2: Recombinant insect cell lysate 24 h.p.i
3: Recombinant insect cell lysate 48 h.p.i
4: Recombinant insect cell lysate 72 h.p.i
5: Recombinant insect cell lysate 96 h.p.i
Figure 3.4.5: Native gel activity assay of insect cell lysates from the time-
course experiments. IEF gel pH 3-10 (BioRad) incubated in 5mM AMP 
and 0.7M Na2SO4, stained with KI/I2.
A: Ala416pygb cell lysates. B: Thr416pygb cell lysates.










Figure 3.4.6: Elution profile of crude insect cell lysate on a High-Q anion 
exchange column. Linear gradient of 0-300mM NaCl applied for elution. The 
recombinant Ala416pygb protein containing fractions indicated on the 
chromatogram. 
Figure 3.4.7: Native gel activity assay of recombinant Ala416pygb 
containing fractions from figure 3.4.6. IEF gel pH 3-10 (BioRad). A: no
allosteric effectors, B: 5mM AMP and 0.7M Na2SO4. Stained with KI/I2.
Key:
Lane 1: Unchallenged Sf9 insect cell lysate
Lanes 2-13: Recombinant Ala416pygb containing fractions






119Figure 3.4.10: SDS-PAGE of 
purified recombinant 
Ala416pygb and Thr416pygb 
proteins. 4-20% Tris-glycine 
polyacrylamide gel, stained with
coomassie blue.
Key:
Lane 1: Ladder (Invitrogen)
Lane 2: Unchallenged Sf9 insect cell  
lysate
Lane 3: Sf9 insect cells infected with 
Ala416PYGB at an MOI of 10.
Lane 4: Purified recombinant 
Ala416pygb protein.
Lane 5: Unchallenged Sf9 insect cell
lysate
Lane 6: Sf9 insect cells infected with 
Thr416PYGB at an MOI of 10.
Lane 7: Purified recombinant 
Thr416pygb protein. 
Lane 1: Ladder (Invitrogen)






Figure 3.4.8: Elution profiles of recombinant pygb’s on a High-Q (BioRad) anion 
exchange column. Linear gradient of 0-300 mM NaCl.
A) Ala416pygb
B) Thr416pygb
Figure 3.4.9: Elution profiles of recombinant pygb’s on a High-Q (BioRad) anion 







Figure 3.4.11: Graphical Representation of V/K vs Pi Concentration (v= 





Figure 3.4.12: Graphical Representation of the effect of Pi on activity of 





Figure 4.4.1: Concanavalin-A (Con A) purification of muscle glycogen 
phosphorylase from ovine semitendinosus muscle. 5μl of 1.5ml column fractions 
analysed via 4-20% Tris-Glycine SDS-PAGE and stained with coomassie blue.
Key:
Lane 1: Protein Ladder (Invitrogen) Lane 2: 1:10 dilution of crude muscle homogenate Lane 3: 1:10 dilution 
of column flow-thru Lane 4: Wash Lanes 5-25: Eluate Lane 26: 5μg of rabbit pygm (Sigma-aldrich)
Figure 4.4.2: Elution profile of pygm 
on High-Q (BioRad) anion exchange 
column. Linear gradient of 0-0.3M 
NaCl
Figure 4.4.3: Elution profile of pygm on 
a Methyl-HIC (BioRad) column. Linear 
gradient of 2.4-0M (NH4)2SO4.
Figure 4.4.4: Concanavalin-A (Con A) purification of liver glycogen 
phosphorylase from ovine liver. 5μl of 1.5ml column fractions analysed via 
4-20% Tris-Glycine SDS-PAGE and stained with coomassie blue.
Key:
Lane 1: Ladder (Invitrogen) Lane 2: 1:10 dilution of crude liver homogenate Lane 3: 1:10 dilution of 






Figure 4.4.5: Elution profile of pygl on 
High-Q (BioRad) anion exchange 
column. Linear gradient of 0- 0.3M 
NaCl.
Figure 4.4.6: Elution profile of pygl on 
High-Q (BioRad) anion exchange 
column. Step gradient of 70mM, 150mM 
and 300mM NaCl.
Figure 4.4.7: Native analysis of 
purified ovine pygm and pygl. 10% 
Tris-Glycine PAGE stained with 
coomassie Blue.
Key:
Lane 1: 2μg rabbit pygm (Sigma-Aldrich)
Lane 2: 5μg purified ovine pygm
Lane 3: 5μg purified ovine pygl
Figure 4.4.8: Native gel activity assay of 
purified ovine pygm and pygl. IEF pH 3-
10 (BioRad), incubated with allosteric 
effectors 5mM AMP and 0.7M Na2SO4.
Key:
Lane 1: 2μg rabbit pygm (Sigma-Aldrich)
Lane 2: 5μg purified ovine pygm









Figure 4.4.9: Native gel activity 
assay of 20μg of ovine tissue 
lysates. IEF pH 3-10 (BioRad) 
incubated in allosteric 
effectors 5mM AMP and 0.7M 
Na2SO4.
Key:
Lane 1: Semitendinosus muscle
Lane 2: Extraocular muscle
Lane 3: Heart 
Lane 4: Brain
Lane 5: Liver














Figure 4.4.10: Native gel activity assay 
of 50μg of ovine tissue lysates. IEF pH 
3-10 (BioRad) incubated in allosteric 
effectors 5mM AMP and 0.7M Na2SO4.
Key:
Lane 1: Normal Heart
Lane 2: McArdle’s Heart
Lane 3: Liver
NB: This is a composite of a larger gel with more 
samples. ‘b’ denotes non-phosphorylated
Figure 4.4.11: Native gel activity assay of 
50μg of ovine tissue lysates. IEF pH 3-10 
(BioRad) incubated in allosteric effectors 
5mM AMP and 0.7M Na2SO4.
Key:
Lane 1: Normal Brain
Lane 2: McArdle’s Brain
Lane 3: Liver
NB: This is a composite of a larger gel with more 







Figure 4.4.12: Western blot analysis of  20μg of ovine tissue lysates to confirm 
antibody specificity. (A) Incubated in pygb antibody 1:10,000 dilution; (B) Incubated 
in pygm antibody 1:1,500 dilution; (C) Incubated in pygl antibody 1:1,000 dilution.




Lane 1: Human muscle, Lane 2: Mouse EDL,
Lane 3: Sheep heart, Lane 4: Mouse heart.
Lane 1: Human muscle, Lane 2: Mouse EDL, 
Lane 3: Mouse liver.
Lane 1: Human muscle, Lane 2: Mouse liver, 
Lane 3: Sheep liver.
Figure 4.4.13: Western blot analysis of mammalian tissues with 






Figure 5.4.1: Northern Blot Analysis of 
Total RNA extracted from ovine 
semitendinosus muscle.
Key:
Lane 1: Normal muscle
Lane 2: McArdle’s muscle #1
Lane 3: McArdle’s muscle #2
Lane 3: McArdle’s muscle #3
Lane 4: Carrier muscle
Figure 5.4.2: Western Blot 
Analysis of total protein lysates 
from ovine semitendinosus 
muscle.
Key:
Lane 1: Normal muscle
Lane 2: McArdle’s muscle #1
Lane 3: McArdle’s muscle #2
Lane 3: McArdle’s muscle #3
Lane 4: Carrier muscle
Figure 5.4.3: Native Gel Activity 
Assay of total protein lysates from 
ovine semitendinosus muscle. 
Incubated with 5mM AMP.
Key:
Lane 1: Normal Semitendinosus
Lane 2: Carrier Semitendinosus
Lane 3: McArdle’s Semitendinosus
pH 10
pH 3
Figure 5.4.4: Kinetic analysis of glycogen 
phosphorylase activity in normal and carrier 
semitendinosus muscle. Note: n= number of 





























1754.6 + 44.1 3867.0  + 160.3










Table 5.4.1: Glycogen phosphorylase assay of 
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Table 5.4.2: Glycogen 
phosphorylase assay of normal and 
McArdle’s affected heart.
Figure 5.4.6: Kinetic analysis of 
glycogen phosphorylase activity 
in normal and McArdle’s affected 
heart. Note: n= number of animal 
samples, each analysed in 
duplicate.
Figure 5.4.7: Native gel activity assay of 
heart from normal, carrier and
McArdle’s affected sheep. IEF pH 3-10 
(BioRad), incubated in allosteric
effectors 5mM AMP and 0.7M Na2SO4.
Lane 1: Normal heart
Lane 2: Carrier heart
Lane 3: McArdle’s affected heart
Lane 4: Normal liver
Note: LL: liver, BB: brain, MB: muscle/brain 















Lane 1: Semitendinosus 
muscle












Figure 5.4.5: Native gel activity assay of control tissue lysates. IEF pH 3-
10 (BioRad), incubated in allosteric effectors 5mM AMP and 0.7M Na2SO4.
Note: LL: liver, BB: brain, MB: muscle/brain hybrid, MM: muscle and ‘b’: non-
phosphorylated. 
Arrow indicates band corresponding to the brain isoform (B) and the suspected 
brain/liver hybrid (A) in brain lysates.
708.7+ 218.9 1409.3  + 65.1
Mean of 3 animals 

































Figure 5.4.8: Western blot 
analysis of heart from 
normal, McArdle’s affected 
and carrier sheep (n=3) with 
polyclonal antibodies 
against A) pygb, B) pygm 
and C) pygl.
Figure 5.4.9: 6μm frozen section from McArdle’s affected extraocular muscle 
stained for glycogen phosphorylase (purple/brown). Arrow indicates
phosphorylase positive intrafusal fibres of the muscle spindle. Magnification 
400x. Image courtesy of Prof. Clive Huxtable.
AB
Figure 5.4.10: Immunohistochemical analysis of 8μm frozen sections of McArdle’s 
affected extraocular muscle with a polyclonal antibody specific for pygb. A) and C) 
pygb (1: 5,000 diln) only, B) and D) overlay with DAPI. Areas of co-localisation are 
purple, pygb postive intrafusal fibres are indicated by arrow. C) and D) peptide 
adsorbed pygb antibody. 
CD
18142  + 12.6 2058.3  + 220.5
Mean of 3 animals 



































































Figure 5.4.13: Western blot 
analysis of extraocular 
muscle from normal,
McArdle’s affected and 
carrier sheep (n=3) with 
polyclonal antibodies 
against A) pygb, B) pygm 
and C) pygl.
Figure 5.4.12: Native gel activity 
assay of extraocular muscle from 
normal, carrier and McArdle’s 
affected sheep. IEF pH 3-10 (BioRad), 
incubated in allosteric effectors 5mM 
AMP and 0.7M Na2SO4.
Lane 1: Normal liver
Lane 2: Normal extraocular
Lane 3: Carrier extraocular
Lane 4: McArdle’s affected extraocular
Note: LL: liver, BB: brain, MM: muscle and ‘b’: 
non-phosphorylated.
Table 5.4.3: Glycogen
phosphorylase assay of 
normal and McArdle’s 
affected extraocular muscle.
Figure 5.4.11: Kinetic analysis of 
glycogen phosphorylase activity 
in normal and McArdle’s affected
extraocular muscle. Note: n= 
number of animal samples, each
analysed in duplicate.
1831    2   3   4














Figure 5.4.14: Native gel 
activity assay of bladder from 
normal, carrier and McArdle’s 
affected sheep. IEF pH 3-10 
(BioRad), incubated in
allosteric effectors 5mM AMP 
and 0.7M Na2SO4.
Lane 1: Normal liver
Lane 2: Normal bladder
Lane 3: Carrier bladder
Lane 4: McArdle’s affected 
bladder
Note: LL: liver, BB: brain, MM: muscle, 
MB: muscle/brain hybrid, LB: 
liver/brain hybrid and ‘b’: non-
phosphorylated.
Figure 5.4.16: Native gel activity 
assay of intestine from normal, 
carrier and McArdle’s affected 
sheep. IEF pH 3-10 (BioRad), 
incubated in allosteric effectors 
5mM AMP and 0.7M Na2SO4.
Lane 1: Normal liver
Lane 2: Normal intestine
Lane 3: Carrier intestine
Lane 4: McArdle’s affected intestine
Note: LL: liver, BB: brain, MM: muscle, LB: 





























Figure 5.4.15: Western blot 
analysis of bladder from 
normal, McArdle’s affected 
and carrier sheep (n=1) with 
polyclonal antibodies 
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Figure 5.4.17: Western blot 
analysis of intestine from 
normal, McArdle’s affected 
and carrier sheep (n=1) with 
polyclonal antibodies 
against A) pygb, B) pygm 
and C) pygl.
Figure 5.4.18: Western blot analysis of tissues from normal and McArdle’s affected 
sheep using polyclonal antibodies against A) pygb, B) pygm and C) pygl. 20μg of 
total protein analysed.
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Figure 5.4.19: Native gel activity assay of normal and McArdle’s affected 
ovine tissues. IEF (BioRad) pH 3-10, incubated in allosteric effectors 5mM 
AMP and 0.7M Na2SO4.
Note: ‘b’ denotes non-phosphorylated isoforms, MM: muscle isoform, MB: 
muscle/brain hybrid, BB: brain isoform, BL: brain/liver hybrid, LL: liver isoform.























MM ‘b’Figure 6.4.3: Northern blot analysis of ovine fetal skeletal muscle using 
a P32 labelled PYGB specific riboprobe. 15μg of total RNA from fetuses
and 5μg of total RNA from adult tissues electrophoresed on a 1%/2.2M 
formaldehyde agarose gel.
Key:
1: 40dE 2: 50dE 3: 60dE 4: 70dE 5: 90dE 6: 110dE 7: 130dE 8: 0dPN 9: 15dPN 10:
adult semitendinosus  muscle 11: adult extraocular muscle 12: adult heart 13: adult 
liver.
Note: E- Embryonic PN-Post-natal
Actual Vs published crown-rump leng

















Figure 6.4.2: Total RNA 
extracted from ovine 
fetal muscle analysed 
on a 1% agarose/TBE 
gel.
Key:
Lane 1: 4μg of mouse liver 
RNA (Ambion)
Lane 2: 2μg of mouse liver 
RNA (Ambion)
Lane 3: 1μg of mouse liver 
RNA (Ambion)
Lanes 4-20: ovine fetal
muscle RNA.
Figure 6.4.1: Crown-rump 
measurements of ovine 
fetuses.
219Figure 6.3.4: Nuclease protection assay of ovine fetal skeletal muscle 
using PYGB (A) and PYGM (B) specific probes. Samples 
electrophoresed on a 5%TBE/Urea polyacrylamide gel and exposed to 
to autoradiography film for 24hrs.
Key: 1: 40dE 2: 50dE 3: 60dE 4: 70dE 5: 80dE 6: 90dE 7: 100dE 8: 110dE 
9: 120dE 10: 130dE 11: 0dPN 12: 15dPN 13: adult semitendinosus  
muscle 14: adult heart 15: adult liver.
Note: E- Embryonic PN-Post-natalA)  4hr exp.
C)  4hr exp.
B)  16hr exp.















Figure 6.4.4: Nuclease protection assay of ovine fetal skeletal muscle 
with riboprobes specific for PYGB  (A&B) and PYGM (C&D).
Key: 
1: Ladder (Ambion) 2: Positive control (protected fragment) 3: 40dE 4: 50dE 5: 60dE 
6: 70dE 7: 80dE 8: 90dE 9: 100dE 10: 110dE 11: 120dE 12: 130dE 13: 0dPN 14:
15dPN 15: adult heart 16: adult semitendinosus  muscle 17: adult liver 18: Ladder 
(Ambion)










































































































Figure 6.4.5: Analysis of PCR products from semi-quantitative RT-PCR of ovine







A) Low Substrate Assay 30mM G-1-P
pH 10
pH 3
B) High Substrate Assay 75mM G-1-P
Figure 6.4.6: Native gel activity assay of 50 μg of ovine fetal skeletal 
muscle on IEF gels (BioRad) pH 3-10, incubated in 5mM AMP and 0.7M 
Na2SO4 and developed with KI/I2.
Key: 1: 40dE 2: 50dE 3: 60dE 4: 70dE 5: 80dE 6: 90dE 7: 100dE 8: 110dE 9: 120dE 
10: 130dE 11: 0dPN 12: 15dPN 13: adult semitendinosus  muscle 14: adult 
extraocular 15: adult heart 16: adult liver 17: adult brain.
Arrow indicates brain isoform in fetal tissues.
Note: E- Embryonic PN-Post-natal. 
‘a’ denotes phosphorylated isoforms, ‘b’ non-phosphorylated isoforms. MM: 
muscle isoform, MB: muscle/brain hybrid, BB: brain isoform, LL: liver isoform
( 20μg of adult lysates analysed in low substrate assay, 10μg of adult lysates 
analysed in high substrate assay.























Figure 6.4.7: Western blot analysis of ovine fetal skeletal muscle with  




1: 40dE 2: 50dE 3: 60dE 4: 70dE 5: 80dE 6: 90dE 7: 100dE 8: 110dE 9: 120dE 10:
130dE 11: 0dPN 12: 15dPN 13: adult extraocular muscle 14: adult semitendinosus 
muscle 15: adult heart 16: adult liver
Figure 6.4.8: Western blot analysis of ovine fetal liver with a  
polyclonal antibody against pygb. 20μg of total protein analysed.
Key:
Lanes
1: 40dE 2: 50dE 3: 60dE 4: 70dE 5: 80dE 6: 90dE 7: 100dE 8: 110dE 9: 120dE 
10: 130dE 11: 0dPN 12: 15dPN 13: adult semitendinosus muscle 14: adult heart 
15: adult brain 16: adult liver
Figure 6.4.9: Native gel activity assay of ovine fetal liver. IEF pH 3-10 
(BioRad), incubated in allosteric effectors 5mM AMP and 0.7M Na2SO4.
Lane markings as in figure 6.4.8.
Note- LL: liver isoform, LB: liver/brain hybrid, BB: brain isoform, MB: muscle/brain 









Figure 6.4.10: Western blot analysis of ovine fetal heart with a polyclonal 
antibody against pygb. 20μg of total protein analysed.
Lanes
1: 40dE 2: 50dE 3: 60dE 4: 70dE 5: 80dE 6: 90dE 7: 100dE 8: 110dE 9: 120dE 10:
130dE 11: 0dPN 12: 15dPN 13: adult semitendinosus muscle 14: adult heart 15: adult 





Figure 6.4.11: Western blot analysis of ovine fetal skeletal muscle from normal 
and McArdle’s affected sheep with polyclonal antibodies against 
A) pygm B) pygb.20μg of total protein analysed.
Lane 1: 130dE Normal
Lane 2: 0dPN Normal
Lane 3: 15dPN Normal
Lane 4: 130dE McArdle’s
Lane 5: 0dPN McArdle’s 
Lane 6: 15dPN McArdle’s
Lane 7: Adult semitendinosus muscle
Lane 8: Adult heart





Figure 6.4.12: Native gel activity 
assay of ovine fetal skeletal muscle 
from normal and McArdle’s affected 
sheep. IEF pH 3-10 (BioRad), 
incubated in the allosteric effectors 
5mM AMP and 0.7M Na2SO4.
Lane 1: Adult liver
Lane 2: Adult brain
Lane 3: Adult heart
Lane 4: Adult semitendinosus muscle 
Lane 5: 130dE Normal
Lane 6: 0dPN Normal
Lane 7: 15dPN Normal
Lane 8: 130dE McArdle’s
Lane 9: 0dPN McArdle’s
Lane 10: 15dPN McArdle’s
NB: LL: liver, BB: brain, MB: muscle/brain hybrid, 
MM: muscle and ‘b’: non-phosphorylated.
pH10
pH3
227Figure 7.4.1: Native gel activity assay of 50μg of muscle biopsy lysate from notexin 
injected McArdle’s lambs. IEF gel pH 3-10 (BioRad), incubated in 5mM AMP and 
0.7M Na2SO4, stained with KI/I2.
Key: 
Lane 1: Uninjected McArdle’s lamb (negative control)
Lane 2: Injected 3 day old McArdle’s lamb 10 day biopsy, 2500 phosphorylase positive fibres.
Lane 3: Injected 4 day old McArdle’s lamb 10 day biopsy, 2000 phosphorylase positive fibres.
Lane 4: Injected 3 day old McArdle’s lamb 30 day biopsy, 200 phosphorylase positive fibres.
Lane 5: Injected 6 day old McArdle’s lamb 30 day biopsy, 300 phosphorylase positive fibres.
Lane 6: Control adult semitendinosus muscle lysate (20μg).
Lane 7: Control adult heart lysate (20μg).
Lane 8: Control adult brain lysate (20μg).
Lane 9: Control adult liver lysate (20μg).
Note: ‘a’ denotes phosphorylated isoforms; ‘b’ denotes non-phosphorylated isoforms; LL: 
Liver isoform; BB: Brain isoform; MM:  Muscle isoform; MB: Muscle/brain hyrbid.
>400 39% < 1 week 60
>300 87% < 1 week 30
>2500 62% > 2 years  10

















Table 7.4.1: Summary of results of phosphorylase positive fibres following 
notexin injection into the hind-limb semitendinosus muscle of 16 McArdle’s 









265Figure 7.4.3: Serial frozen sections (6μm) of a 10 day semitendinosus muscle 
biopsy from a notexin injected McArdle’s lamb. Stained for glycogen 
phosphorylase (A) and glycogen (B). Phosphorylase positive fibres are stained 
purple/brown. Red box indicates areas of phosphorylase expression and reduced 





Figure 7.4.2: Western blot 
analysis of 20μg of 
muscle biopsy lysate 
from notexin injected 
McArdle’s lambs.
(A) pygb antibody 
(1:10,000 dilution)
(B) pygl antibody (1:1,000 
dilution)
(C) pygm antibody 
(1:1,500 dilution)
Key: 
Lane 1: Uninjected McArdle’s lamb (negative control)
Lane 2: Injected 3 day old McArdle’s lamb 10 day biopsy, 2500 phosphorylase positive fibres.
Lane 3: Injected 4 day old McArdle’s lamb 10 day biopsy, 2000 phosphorylase positive fibres.
Lane 4: Injected 3 day old McArdle’s lamb 30 day biopsy, 200 phosphorylase positive fibres.
Lane 5: Injected 6 day old McArdle’s lamb 30 day biopsy, 300 phosphorylase positive fibres.
Lane 6: Control adult semitendinosus muscle lysate (20μg).
Lane 7: Control adult heart lysate (20μg).
Lane 8: Control adult brain lysate (20μg).
Lane 9: Control adult liver lysate (20μg).
267Figure 7.4.7: Western blot analysis with pygm antibody, of 20μg of muscle
lysate from McArdle’s affected lambs injected wither AdVCMVPYGM or 
AAVCMVPYGM vectors.
Key:
Lane 1: 3day old lamb uninjected (negative control)
Lane 2: 3month old lamb injected with AAVCMVPYGM, 20day biopsy, 900 phosphorylase positive fibres.
Lane 3: 2day old lamb injected with AdVCMVPYGM, 30day biopsy, 5000 phosphorylase positive fibres.
Lane 4: 2day old lamb injected with AdVCMVPYGM, 10day biopsy, 3200 phosphorylase positive fibres.
Lane 5: 3day old lamb injected with AAVCMVPYGM, 40day biopsy, 4500 phosphorylase positive fibres.
Lane 6: 5μg of sheep control muscle
Lane 7: 20μg of sheep control heart
Lane 8: 20μg of sheep control liver
Lane 9: 20μg of human control muscle
Figure 7.4.6: Native gel activity assay of 50μg of muscle lysate from McArdle’s 
affected lambs injected wither AdVCMVPYGM or AAVCMVPYGM vectors. IEF gel 
pH 3-10 (BioRad), incubated in 5mM AMP and 0.7M Na2SO4, stained with KI/I2.
Key:
Lane 1: 5μg of human control muscle
Lane 2: 3month old lamb injected with AAVCMVPYGM, 20day biopsy, 900 phosphorylase positive fibres.
Lane 3: 2day old lamb injected with AdVCMVPYGM, 30day biopsy, 5000 phosphorylase positive fibres.
Lane 4: 2day old lamb injected with AdVCMVPYGM, 10day biopsy, 3200 phosphorylase positive fibres.
Lane 5: 3day old lamb injected with AAVCMVPYGM, 40day biopsy, 4500 phosphorylase positive fibres.
Lane 6: 5μg of sheep control muscle
Lane 7: 10μg of sheep control heart
Lane 8: 10μg of sheep control liver
Note: ‘b’ denotes non-phosphorylated isoforms; LL: Liver isoform; BB: Brain isoform; MM:  Muscle
isoform; MB: Muscle/brain hyrbid.
100kDa
275